English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduCastleVax, a clinical stage vaccine platform company, has received a Project NexGen award valued at up to $338 million from the Biomedical Advanced Research and Development Authority (BARDA), to support the development of a next-generation, booster vaccine to protect against COVID-19 for years to come.
Tag: Mount Sinai Innovation Partners
Promising Results of Next-Generation Intranasal COVID-19 Booster Vaccine: Implications for Infection Prevention and Transmission
The Icahn School of Medicine at Mount Sinai in New York, NY is pleased to announce that CastleVax, Inc. has completed enrollment and a preliminary analysis of a phase 1 trial of its licensed Newcastle disease virus (NDV)-based COVID-19 booster vaccine.
Mount Sinai Awarded $11.6 Million Grant to Launch Comprehensive Center for Surgical Innovation and Expand Mount Sinai BioDesign
In a move that has the potential to change the future of surgery, advance quality care, and bring economic growth to New York City, Mount Sinai Health System announced today the launch of the Comprehensive Center for Surgical Innovation (CCSI).
Mount Sinai Announces the Formation of CastleVax Inc., a Clinical-Stage Infectious Diseases Company Developing Novel Vaccines and Therapeutics, Targeting Pandemic Threats and Diseases of Unmet Medical Need
The Mount Sinai Health System has launched CastleVax, Inc. (“CastleVax”), a clinical-stage vaccine research and development company.
Mount Sinai Health System Launches Elementa Labs, A Virtual Incubator Program
Elementa Labs will connect health care startup companies with Mount Sinai’s vast network of research and clinical experts to advance groundbreaking health care innovations.
Mount Sinai seeks EUA from Food and Drug Administration for potential quantitative serologic test for COVID-19
If authorized for quantitative use, the assay could be used to provide a numeric result for the concentration of neutralizing anti-COVID-19 antibodies in plasma.
Mount Sinai Health System and Renalytix Form Joint Venture, Kantaro Biosciences, To Develop and Scale Production of COVID Antibody Test Kits
– Kantaro Biosciences partners with Bio-Techne for manufacturing and global kit distribution
– Scaled kit production to enable clinical laboratories to conduct 10M tests per month is planned to begin in July
Mount Sinai and Harbour BioMed Collaborate to Advance Novel Biotherapies for the Treatment of Cancer and Coronavirus COVID-19
Collaboration combines Harbour BioMed’s proprietary H2L2 Harbour Mice® platform for fully human monoclonal antibody generation with Mount Sinai’s translational medical research expertise.